Thomas Lodise

Summary

Affiliation: Albany College of Pharmacy
Country: USA

Publications

  1. pmc Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity
    Thomas P Lodise
    Department of Pharmacy Practice, Albany College of Pharmacy, Albany, NY 12208, USA
    Antimicrob Agents Chemother 52:1330-6. 2008
  2. pmc Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection
    Thomas P Lodise
    Albany College of Pharmacy, Pharmacy Practice, Albany College of Pharmacy, Albany, NY 12208 3492, USA
    Antimicrob Agents Chemother 51:3510-5. 2007
  3. pmc Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin
    T P Lodise
    Department of Pharmacy Practice, Albany College of Pharmacy, Albany, New York 12208 3492, USA
    Antimicrob Agents Chemother 52:3315-20. 2008
  4. pmc Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients
    N Patel
    Albany College of Pharmacy and Health Sciences, Albany, New York 12208, USA
    Antimicrob Agents Chemother 54:460-5. 2010
  5. ncbi request reprint Burden of methicillin-resistant Staphylococcus aureus: focus on clinical and economic outcomes
    Thomas P Lodise
    Department of Pharmacy Practice, Albany College of Pharmacy, Albany, New York 12208 3492, USA
    Pharmacotherapy 27:1001-12. 2007
  6. pmc Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation
    Thomas P Lodise
    Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208 3492, USA
    Antimicrob Agents Chemother 52:2300-4. 2008
  7. doi request reprint Pharmacokinetic and pharmacodynamic profile of ceftobiprole
    Thomas P Lodise
    Albany College of Pharmacy, Albany, NY 12208, USA
    Diagn Microbiol Infect Dis 61:96-102. 2008
  8. ncbi request reprint Effects of gatifloxacin and levofloxacin on rates of hypoglycemia and hyperglycemia among elderly hospitalized patients
    Thomas Lodise
    Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208 3492, USA
    Pharmacotherapy 27:1498-505. 2007
  9. ncbi request reprint Identification of patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk of infection with carbapenem-resistant isolates
    Thomas P Lodise
    Pharmacy Practice Department, Albany College of Pharmacy, Albany, NY 12208, USA
    Infect Control Hosp Epidemiol 28:959-65. 2007
  10. pmc Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus
    Thomas P Lodise
    Albany College of Pharmacy, Albany, NY 12208 3492, USA
    Antimicrob Agents Chemother 51:3731-3. 2007

Detail Information

Publications33

  1. pmc Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity
    Thomas P Lodise
    Department of Pharmacy Practice, Albany College of Pharmacy, Albany, NY 12208, USA
    Antimicrob Agents Chemother 52:1330-6. 2008
    ..6 ml/min, and intensive care unit residence were independently associated with time to nephrotoxicity. The data suggest that higher-dose vancomycin regimens are associated with a higher likelihood of vancomycin-related nephrotoxicity...
  2. pmc Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection
    Thomas P Lodise
    Albany College of Pharmacy, Pharmacy Practice, Albany College of Pharmacy, Albany, NY 12208 3492, USA
    Antimicrob Agents Chemother 51:3510-5. 2007
    ..The data strongly suggest that delaying appropriate therapy for approximately 2 days significantly increases the risk of 30-day mortality in patients with P. aeruginosa bloodstream infections...
  3. pmc Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin
    T P Lodise
    Department of Pharmacy Practice, Albany College of Pharmacy, Albany, New York 12208 3492, USA
    Antimicrob Agents Chemother 52:3315-20. 2008
    ..4; P = 0.01). These data strongly suggest that patients with MRSA bloodstream infections with vancomycin MICs of >or=1.5 mg/liter respond poorly to vancomycin. Alternative anti-MRSA therapies should be considered for these patients...
  4. pmc Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients
    N Patel
    Albany College of Pharmacy and Health Sciences, Albany, New York 12208, USA
    Antimicrob Agents Chemother 54:460-5. 2010
    ..The CL(CR) adjustments for traditional and extended-infusion TZP dosing regimens should be considered at a CL(CR) of <or=20 ml/min...
  5. ncbi request reprint Burden of methicillin-resistant Staphylococcus aureus: focus on clinical and economic outcomes
    Thomas P Lodise
    Department of Pharmacy Practice, Albany College of Pharmacy, Albany, New York 12208 3492, USA
    Pharmacotherapy 27:1001-12. 2007
    ..Further studies are needed to determine if these drugs can better eradicate MRSA than vancomycin and remedy the adverse outcomes frequently observed with this organism...
  6. pmc Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation
    Thomas P Lodise
    Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208 3492, USA
    Antimicrob Agents Chemother 52:2300-4. 2008
    ..The median AUC(ELF)/free AUC(plasma) penetration ratio was 0.73, and the 25th and 75th percentile value ratios were 0.43 and 1.24, respectively. In uninfected lung tissue, the median AUC(ELF) is approximately 75% of the free AUC(plasma)...
  7. doi request reprint Pharmacokinetic and pharmacodynamic profile of ceftobiprole
    Thomas P Lodise
    Albany College of Pharmacy, Albany, NY 12208, USA
    Diagn Microbiol Infect Dis 61:96-102. 2008
    ....
  8. ncbi request reprint Effects of gatifloxacin and levofloxacin on rates of hypoglycemia and hyperglycemia among elderly hospitalized patients
    Thomas Lodise
    Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208 3492, USA
    Pharmacotherapy 27:1498-505. 2007
    ....
  9. ncbi request reprint Identification of patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk of infection with carbapenem-resistant isolates
    Thomas P Lodise
    Pharmacy Practice Department, Albany College of Pharmacy, Albany, NY 12208, USA
    Infect Control Hosp Epidemiol 28:959-65. 2007
    ..aeruginosa infections and potentially maximize clinical outcomes by increasing the likelihood of appropriate empirical antimicrobial therapy...
  10. pmc Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus
    Thomas P Lodise
    Albany College of Pharmacy, Albany, NY 12208 3492, USA
    Antimicrob Agents Chemother 51:3731-3. 2007
    ....
  11. pmc Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia
    Thomas P Lodise
    Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208 3492, USA
    Antimicrob Agents Chemother 51:3977-82. 2007
    ..01]), but no difference in LOS was noted among PSI class V patients. Our study showed that improved outcomes may be realized with BL+M in cases of severe CAP. A randomized clinical study is warranted based on these results...
  12. ncbi request reprint Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy
    Thomas P Lodise
    Department of Pharmacy Practice, Albany College of Pharmacy, Albany, NY 12208, USA
    Clin Infect Dis 44:357-63. 2007
    ..This study evaluates the clinical implications of extended infusion of piperacillin-tazobactam therapy for critically ill patients with P. aeruginosa infection...
  13. pmc Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance
    Thomas P Lodise
    Albany College of Pharmacy, Department of Pharmacy Practice, and Department of Pharmacy, Albany Medical Center Hospital, 106 New Scotland Avenue, Albany, NY 12208 3492, USA
    Antimicrob Agents Chemother 51:417-22. 2007
    ..aeruginosa respiratory tract infections at our institution. Identifying these risk factors enabled us to develop a prediction tool to assess the risk of resistance and thus guide empirical antibiotic therapy...
  14. ncbi request reprint Pharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies
    Thomas P Lodise
    Department of Pharmacy Practice, Albany College of Pharmacy, Albany, NY 12208, USA
    Diagn Microbiol Infect Dis 54:223-30. 2006
    ..03 and 8 microg/mL for each regimen examined. In CSF, none of the regimens achieved 50-100% T>MIC for>80% of patients for MICs>0.5 mg/L...
  15. ncbi request reprint Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia
    Thomas P Lodise
    Department of Pharmacy Practice, Albany College of Pharmacy, Albany, NY 12208, USA
    Diagn Microbiol Infect Dis 52:113-22. 2005
    ..With the advent of new treatment options, the impact of MRSA will need to be revisited to determine if these therapies can remedy the increased morbidity associated with MRSA...
  16. doi request reprint Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia
    T P Lodise
    Albany College of Pharmacy, Department of Pharmacy Practice, Albany, NY 12208 3492, USA
    J Antimicrob Chemother 62:1138-41. 2008
    ..5 mg/L). However, scant research exists on factors predictive of high vancomycin MICs (> or = 1.5 mg/L) among MRSA bacteraemic patients. Empirical therapy decisions would greatly benefit from such information...
  17. doi request reprint Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients
    Thomas P Lodise
    Dept of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, 106 New Scotland Ave, Albany, NY 12208, USA
    Clin Infect Dis 49:507-14. 2009
    ..No study has been undertaken to determine the pharmacodynamic index (ie, the area under the curve [AUC] or the trough value) that best describes the relationship between vancomycin exposure and onset of nephrotoxicity...
  18. pmc Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects
    Thomas P Lodise
    Ordway Research Institute, Albany, NY 12208, USA
    Antimicrob Agents Chemother 51:2378-87. 2007
    ..v. q12h, for patients who had a creatinine clearance rate of < or =50 ml/min, was identified as the most appropriate treatment regimen for patients who require renal dose adjustment for mild to moderate renal impairment...
  19. pmc Relationship between various definitions of prior antibiotic exposure and piperacillin-tazobactam resistance among patients with respiratory tract infections caused by Pseudomonas aeruginosa
    Nimish Patel
    Albany College of Pharmacy, Department of Pharmacy Practice, 106 New Scotland Avenue, Albany, NY 12208 3492, USA
    Antimicrob Agents Chemother 52:2933-6. 2008
    ..When the specific antibiotic used was replaced by the number of prior exposures, the number of exposures was the only variable associated with an increased risk of antibiotic resistance at each time threshold...
  20. ncbi request reprint Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy
    Christopher D Miller
    Department of Pharmacy Practice, Albany College of Pharmacy, Albany, New York 12208, USA
    Pharmacotherapy 27:1379-86. 2007
    ....
  21. pmc Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation
    Thomas P Lodise
    Albany College, Albany, New York, USA
    Antimicrob Agents Chemother 48:4718-24. 2004
    ..This study indicates that piperacillin-tazobactam should have utility for empirical therapy of hospital-onset infections...
  22. ncbi request reprint Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens
    Thomas P Lodise
    Albany College of Pharmacy, Albany Medical College, Albany, NY 12208, USA
    Diagn Microbiol Infect Dis 52:45-52. 2005
    ..1% for H. influenzae. This study demonstrated a relationship between telithromycin drug exposure and microbiological outcome. Telithromycin is expected to achieve the drug exposure breakpoint for the majority of isolates causing CAP...
  23. pmc Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin
    Kerry L LaPlante
    Anti Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Department of Pharmacy Practice, School of Medicine, Wayne State University, 259 Mack Ave, Detroit, MI 48201, USA
    Antimicrob Agents Chemother 51:1315-20. 2007
    ..002) than those of gatifloxacin. The order of resistance development determined from fAUC/MIC breakpoints was levofloxacin>gatifloxacin>moxifloxacin=gemifloxacin, which may be related to structural differences within the class...
  24. ncbi request reprint Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists
    Thomas P Lodise
    Albany College of Pharmacy, Albany, New York 12208, USA
    Pharmacotherapy 26:1320-32. 2006
    ..Moreover, they achieved the targeted fT>MIC with less administration time/day than would be needed for continuous infusion...
  25. pmc Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms
    Sunil V Bhat
    Division of Infectious Diseases, University of Pittsburgh Medical Center, Suite 3A Falk Medical Building, 3601 Fifth Avenue, Pittsburgh, PA 15213, USA
    Antimicrob Agents Chemother 51:4390-5. 2007
    ....
  26. ncbi request reprint Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia
    Thomas P Lodise
    Anti Infective Research Laboratory, Detroit Receiving Hospital and University Health Center, Detroit, MI, USA
    Clin Infect Dis 36:1418-23. 2003
    ..2 days versus 14.3 days; P=.05). These findings support the notion that delay of therapy has deleterious effects on clinical outcomes, and efforts should be made to ensure that appropriate therapy is initiated promptly...
  27. ncbi request reprint Prediction model to identify patients with Staphylococcus aureus bacteremia at risk for methicillin resistance
    Thomas P Lodise
    Anti Infective Research Laboratory, Detroit Receiving Hospital, Wayne State University, 4201 St Antoine Blvd, 1 B UHC, Detroit, MI 48201, USA
    Infect Control Hosp Epidemiol 24:655-61. 2003
    ..To identify institution-specific risk factors for MRSA bacteremia and develop an objective mechanism to estimate the probability of methicillin resistance in a given patient with Staphylococcus aureus bacteremia (SAB)...
  28. ncbi request reprint Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections
    Bong K Yoo
    College of Pharmacy, Yeungnam University, Dae dong Kyungsan si, South Korea
    Ann Pharmacother 38:1226-35. 2004
    ....
  29. ncbi request reprint Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia
    C Andrew DeRyke
    Center for Anti Infective Research and Development, Hartford Hospital, CT, USA
    Chest 128:1414-22. 2005
    ..To describe outcomes associated with nosocomial bacteremic Staphylococcus aureus pneumonia (NBSAP) and to determine whether delay in adequate antimicrobial treatment is a risk factor for negative clinical and microbiological outcomes...
  30. pmc Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid
    Thomas P Lodise
    Institute for Biomedical and Pharmaceutical Research, N├╝rnberg Heroldsberg, Germany
    Antimicrob Agents Chemother 52:1945-51. 2008
    ..06 mg/liter, which includes most S. pneumoniae isolates with intermediate susceptibility to penicillin, when given in the fasting state in both plasma and ELF...
  31. ncbi request reprint Comparison of the probability of target attainment between ceftriaxone and cefepime in the cerebrospinal fluid and serum against Streptococcus pneumoniae
    Thomas P Lodise
    Institute for Biomedical and Pharmaceutical Research, N├╝rnberg Heroldsberg, 90562 Germany
    Diagn Microbiol Infect Dis 58:445-52. 2007
    ..8% and 82%, respectively. The CSF pharmacodynamics against S. pneumoniae for cefepime were superior to that of ceftriaxone. The implications of these findings need to be reexamined in the clinical setting...
  32. ncbi request reprint A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients
    Jessina C McGregor
    Oregon State University College of Pharmacy, Portland, OR 97239, USA
    Clin Infect Dis 45:329-37. 2007
    ..In brief, future studies should define "inappropriate" therapy on the basis of in vitro susceptibility data, should separately evaluate empiric and definitive therapy, and should control for the baseline severity of illness...
  33. ncbi request reprint Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center
    Thomas P Lodise
    Anti Infective Research Laboratory, Detroit Receiving Hospital, Wayne State University, Detroit, MI, 48201, USA
    Clin Infect Dis 34:922-9. 2002
    ..7plus minus1.88 vs. 15.9 +/- 1.7, P=.006). These observations indicate that vancomycin resistance in EB independently affects outcomes...